Four s fortnightly pharma health track 23th january - 5th febuary 2012

  • 635 views
Uploaded on

Four-S Services - Research

Four-S Services - Research

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
635
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. FOUR-S PharmaHealth Track 23thJan– 5thFeb’11 PharmaHealth TRACK Newsletter on Indian Healthcare Industry Top Story Content Results Update Private Equity 2 Healthcare Pharma sector has seen overall positive results this quarter. Sector has shown strong 28% y-o-y growth in revenue Mergers & Acquisitions 3 for the major companies with results declared till now. Though profit has seen the muted growth this quarter as many companies has seen decrease in net margin q-o-q basis. News Update 4 Dr Reddys Laboratories Q3 net profit at `5129.60 mn Regulatory Developments 6 Drug firm Dr Reddys Laboratories consolidated net profit rose Upcoming Events 7 by 87.80 per cent to `5129.6mn in the third quarter ended December 31, 2011 vis-a-vis the corresponding year-ago period. The company had posted a net profit of `2731.4mn for Stock Market Update 8 the corresponding period of the previous fiscal. Companys net income from sales and services rose to `27691.9mn in the third Peer Benchmarking 8 quarter ended December 31, 2011, from `18,985.1mn for the same period last fiscal. Companys net income from sales and services rose to `27,691.9mn in the third quarter ended About Four-S Services 10 December 31, 2011, from `18,985.1mn for the same period last fiscal. For the nine months ended December 31, 2011, the company posted a net profit of `10,835mn, compared to `7,695.1mn for the same period last fiscal.About Four-S ServicesFour-S Services is Indias leading provider of Research, Financial Consulting and Investment Banking services with offices in Gurgaon, Mumbai andBangalore. We have a proven track record of consistently delivering high quality solutions, enabling our clients to improve the effectiveness of decisionmaking and acting as a catalyst in achieving business success. We have executed more than 120 mandates across diverse range of industries includingEducation, Financial Services, Infrastructure, M&E, IT-ITeS, Auto and Auto ancillaries, Retail, Real Estate and Textile etcOur Services:  Strategy Consulting  Research Support  Business Planning  Valuation Services  Investment Banking  Investor Relations & IPO ConsultingFor further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.comResearch DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projects forprestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s Top 5 PEFunds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
  • 2. FOUR-S PharmaHealth Track Investment Activity last 1 year..Date Investor(s) Target Stake (%) Amount ($mn) Business Stage Aizant Drug Research NA17-Jan-2011 Zephyr Peacock India 5.0 CRO Early Solutions Ltd Integrated Health & NA18-Jan-2011 Halcyon Capital Advisor 44.2 Hospitals Buyout Healthcare Services Sequoia Capital, Elevar NA28-Jan-2011 Glocal Healthcare Systems 3.3 Hospitals Early Equity15-Apr-2011 Avigo Capital SRL 9.27 224 Diagnostics Growth5-May-2011 Sabre Partners SRL 4 112 Diagnostics Growth Aquarious India,17-Jun-2011 Vaatsalya NA 10 Hospitals Growth SeedFund Catamaran, Reliance VA,20-Jun-2011 Wellspring Healthcare NA 4.6 Hospitals Growth Bluecross BlueShield VP23-Jun-2011 HDFC PE Angels Health Pvt Ltd 12 0.6 Online Healthcare Early Super specialty10-Aug-2011 Matrix Partners Kids Clinic NA 10 Early hospital chain28-Sep-2011 Sequoia Capital Moolchand Medcity NA 22.0 Hospitals Growth Helion Ventures, Nexus10-Oct-2011 Eye-Q NA NA Hospitals Growth Ventures28-Nov-2011 Fidelity Growth Partners XCyton Diagnostics NA NA Diagnostics Growth12-Jan-2012 NEA, DaVita Inc NephroLife Care NA 25.0 Hospitals Growth Sequoia Capital,11-Jan-2012 Healthkart.Com NA 5.1 Health Services Early Omidyar Network18-Jan-2012 Olympus Capital DM Healthcare NA 100.0 Hospitals Growth20-Jan-2012 Songs Investments Be Well Hospitals NA NA Hospitals Growth OrbiMed, Ascent Kerala Institute of Medical25-Jan-2012 NA 33.3 Hospitals Late Capital Science Source: Four-S Database Four-S Indian PE Directory 2010” – A Guide to choosing private equity partners  Detailed listing of ~330 Active PE/VC Investors in India - PE/VC players that have invested in the past 3 years.  A first-of-its-kind, the directory offers “Deal History” in India for individual investor.  Management, investment profile and Contact details.  User-friendly Spreadsheet Format.  It comes from Four-S Services, the most trusted deal information bank in India. Research Desk Four-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projects for prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s Top 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
  • 3. FOUR-S PharmaHealth TrackMergers & AcquisitionDate Investor(s) Target Stake Amount ($mn) Business (%)19-Jan 2011 Transasia Bio-Medicals Diasis Diagnostic Systems NA NA Diagnostics20-Jan 2011 Surya Pharmaceuticals ActivOn NA 22.3 Pharma Bioserve Clinical Research Private23-Feb-2011 QPS Holdings Limited NA NA Clinical Research15-Apr-2011 Ecron Ecunova aCROnordic 75% 3.4 CRO15-Apr-2011 Hikma Pharmaceuticals Unimark Remedies 22.2% 33.3 Pharma15-Apr-2011 Fortis Healthcare SRL 86% 189.4 Diagnostics15-Jun-2011 Lupin Goanna Brand NA NA OTC17-Jun-2011 Zydus Nesher Pharma unit NA NA Generic19-Jul-2011 Shilpa Medicare Nu Therapeutics 50 NA Pharma21-Jul-2011 Dr Reddy’s Laboratories JBCL-Russia-CIS prescription products 100 30.5 Pharma28-Jul-2011 Cadila Healthcare Bremer Pharma 100 NA Pharma3-Aug-2011 Danone Wockhardt s nutrition business 100 355 Pharma9-Aug-2011 Ipca Labs Onyx Research 100 7.5 Healthcare Services10-Aug-2011 Fortis Hoan My Medical 65 64 Hospitals12-Sep-2011 Vivimed Labs Octtantis Nobel Labs Ltd 50 NA Pharma8-Oct-2011 Akorn Inc KilitchDrugs (India) Ltd NA 40.1 Pharma12-Oct-2011 Life Healthcare Group Max Healthcare Ltd. NA 103.1 Hospitals Universal Medicare - branded Pharma4-Nov-2011 Aventis Pharma nutraceutical formulations biz NA 114.0 Shalaks Pharmaceuticals - Pharma14-Nov-2011 Invida Group dermatology and baby care 100 19.118-Nov-2011 Lupin Limited Irom Pharma 100 NA Pharma24-Nov-2011 SOHM Inc Novatrend Medicament NA NA Pharma Transgene Biotek bio generic product Pharma23-Nov-2011 TSS EXPORT GmbH FZE - Erythropoietin 100 5.028-Nov-2011 Vivimed Labs Uquifa 100 55.0 Pharma17-Jan-2012 Dishman Pharma Creapharm Parenterals 100 NA Pharma24-Jan-2012 Watson Pharmaceuticals Ascent Pharma Health Ltd. NA 393 Pharma1-Feb-2012 Fortis Healthcare RadLink-Asia Pte Ltd 85 50 Diagnostic2-Feb-2012 Aanjaneya Lifecare Apex Drugs and Intermediaries Ltd 100 50 Pharma Source: Four-S DatabaseResearch DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projects forprestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s Top 5 PEFunds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
  • 4. FOUR-S PharmaHealth Track News UpdateHealthcare & Pharmaceutical Sector Pfizer posts profit of `482.8mn in Q31.) Pharmaceutical Sector Pfizer Ltd reported a net profit of `482.8mn and a net profit of `435.8mn for the third quarter ended December 31, 2011. NetResult Update Continue…. sales of the company stood at `2518.8mn for the third quarter ended December 31, 2011 compared to `2358.4mn for the thirdPiramal Healthcare Q3 cons net profit at `85.20 mn quarter ended November 30, 2010. For the nine months ended December 31, 2011, the company posted a net profit ofPiramal Healthcare Ltd has posted a net profit of `85.20 mn for `1365.1mn compared to `1207.5mn for the third quarter endedthe quarter ended December 31, 2011 whereas the same was November 30, 2010.at `603.30 mn for the quarter ended December 31, 2010. TotalIncome is `6175.70 mn for the quarter ended December 31, TCG Lifesciences completes key milestones on delivery of2011 whereas the same was at `5348.80 million for the quarter pre-clinical drug candidatesended December 31, 2010. TCG Lifesciences Limited (TCGLS) announced the achievement ofFor Q3FY2012, Pharma Solutions (CRAMS) business registered two distinct milestones in their ongoing drug discoverystrong growth of 57.4% with sales of `3.673bn as compared to partnership with Endo Pharmaceuticals. TCGLS will receive`2.334bn in Q3FY2011. The revenues from Indian facilities grew undisclosed success fees against these milestones.by 68.9 % to `2.24bn.Divis Labs Q3 profit up 20.65 pc at `1225.5mn In the first of two fully integrated discovery programs with Endo aimed at identifying novel small molecule drug candidates for anDrug firm Divis Laboratories net profit rose by 20.65 per cent to unmet medical need, TCGLS has successfully delivered a pre-`1225.5mn for the third quarter ended December 31, 2011 clinical development candidate. In the second, TCGLS hascompared to a net profit of `1015.7mn for the quarter ended designed and delivered novel fast-follower hit structures wellDecember 31, 2010. Total income of the company stood at within collaboration timelines. This multi-year, three-stage`4,174.2mn for the quarter ended December 31, 2011 as project aims to identify potent in-vivo active novel blockers ofagainst `3,149.7mn for the corresponding period previous fiscal an undisclosed target for eventual clinical development.Lupin Q3 net up 4.95% at `2351mn Two lead molecules resulting from this collaboration have been selected by Endo for cGMP manufacturing and GLP-toxicologyDrug firm Lupin consolidated net profit rose by 4.95 per cent to studies.`2,351mn for the third quarter ended December 31, 2011compared to net profit of `2240mn for the corresponding Pfizer recalls 1 mn packets of birth control pillsperiod of previous fiscal. Net sales of the company grew by 21.9per cent to `17,917mn for the third quarter, compared to American pharmaceutical giant Pfizer has announced recall of`14,694mn in the same period previous fiscal. more than one million packets of birth control pills after it found out that inactive or placebo pill may have been placed out-of-Glenmark Pharma Q3 net profit down 46% order in some packs. Company has announced a voluntary recall of Lo/Ovral-28 (norgestrel and ethinyl estradiol) and NorgestrelGlenmark Pharmaceuticals Ltd has posted a net profit after tax and Ethinyl Estradiol Tablets (generic) birth control pills in theof `461.18 million for the quarter ended December 31, 2011 as United States. Its voluntary recall is based on its own internalcompared to `865.25 million for the quarter ended December assessments of this problem, in which it found that the inactive31, 2010. Total Income has increased from `7732.79 million for or placebo pill may have been placed out-of-order in somethe quarter ended December 31, 2010 to `10418.45 million for packs.the quarter ended December 31, 2011. The company took a hitof `1.02bn on dollar denominated loans due to rupee State Bank of Mysore files criminal complaint againstdepreciation. During the quarter, net sales stood at Sterling Biotech for repayment dafault`10,310.8mn as against `7486.4mn in the corresponding periodprevious fiscal State Bank of Mysore has filed a criminal complaint against Sterling Biotech, and its six directors, for allegedly defaulting on repayments on credit facilities provided by the public sector lender.Research DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projectsfor prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’sTop 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
  • 5. FOUR-S PharmaHealth TrackIn its complaint, the bank has said that cheques worth 580mn Piramal Group picks up an additional 5.5% stake insubmitted by the company have bounced. The cheques were Vodafone India for `30.07bndrawn on Andhra Bank. Sterling Biotech is the flagship companyof Gujarat-based Sandesara Group. Sterling Biotech has 7.5% Piramal Healthcare Ltd would buy a 5.5 per cent stake instake in the world gelatin market and has 60% share in the local Vodafones India unit, Essar, for `30.07bn ($616.14 million),market. taking its total stake in the mobile company to about 11 per cent.Indoco Remedies signs strategic pact with DSM Pharma The sale would mark the exit of Essar as Vodafones jointIndoco Remedies Ltd. has entered into a strategic business venture partner in India after the London-listed company lastalliance with DSM Pharmaceutical Products NV. DSM year sealed a long awaited deal to buy out Essar in July.Pharmaceutical Products NV is a constituent of the Royal DSM Vodafone last year bought 22 per cent of Essar and PiramalNV, Austria. bought 5.5 per cent.Under the agreement reached, DPP will market and sell eight The transaction contemplates various exit options for Piramal,active pharma ingredients (APIs) manufactured by Indoco in including both participation in a potential IPO of the unit and aAustria and other international markets. sale of its stake back to VodafoneFondaparinux injection issue resolved with USFDA: Dr 2.) HealthcareReddys Laboratories Fortis Healthcare arm acquires 85% stake in RadLink-AsiaDrug firm Dr Reddys Laboratories has resolved all issues raisedby a division of US health regulator over its promotional Fortis Healthcare Singapore Pte, Fortis Healthcare India offshorematerial for an anti-coagulant injection. subsidiary, has acquired 85% stake in RadLink-Asia Pte Ltd ("RadLink"), an outpatient diagnostic and molecular imagingOffice of Prescription Drug Promotion (OPDP) had issued a letter chain in Singapore, for a purchase consideration of S$62.9to the company for changes related to certain promotional million.material for Fondaparinux Sodium for Injection. The companyhas already addressed all matters raised by the Division of The transaction provides Fortis Healthcare a strong foothold inProfessional Promotion (DPP), USFDA in the letter issued on the premium diagnostics and molecular imaging segment in oneJanuary 10, 2012. The DPP informed Dr Reddys Lab on January of Southeast Asias most attractive markets besides providing a24, 2012 that the matters are now considered closed. complementary platform to its upcoming specialty hospital on Adam Road in Singapore.OPDP through the letter had intimated to the Hyderabad- baseddrug firm that the companys information on a promotional Radlink has four main business segments; diagnostic imaging,website for Fondaparinux Sodium Solution for subcutaneous molecular imaging, cyclotron (radio-isotopes manufacturing)injection was misleading. and GP clinics.US drugmaker Eli Lilly, Jubilant Life call off joint venture Fortis Healthcare invests SGD70 million in 2 Singapore healthcare venturesUS drugmaker Eli Lilly & Company and Noida-based JubilantLife Sciences have called off their equal drug-discovery Indian healthcare group Fortis is investing SGD 70 million (aboutpartnership to develop molecules across several therapeutic `2.74bn) in two colorectal centres in Singapore this year. Fortisareas. Healthcare Singapore had opened a outpatient clinic for colorectal diseases, Novena Colorectal Centre, and a 31-The 50:50 JV, formed in late 2008 between Jubilant Life bed Fortis Hospital for Colorectal Diseases in June this year.Sciences wholly-owned subsidiary Jubilant Biosys and Lilly, was Fortis has started hiring nurses and allied health professionalsto develop molecules from the pre-clinical to phase II stage for 80 positions at the clinic and hospital. The hospital wouldacross oncology, diabetes and cardiovascular segments. The firm serve 40 patients a day while the clinic would be a groupis called Vanthys Pharmaceuticals and based in Bangalore. practice by four colorectal specialists who also have deeper expertise in areas such as robotic surgery to genetic testing.Research DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projectsfor prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’sTop 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
  • 6. FOUR-S PharmaHealth TrackFortis to raise US$300mn via IPO of non-core biz written records, not prevented contamination of sterile drugs at its facilities, inadequately tested drugs, and submitted false dataFortis Healthcare (India) is planning to raise $300 mn by spinning to the FDA. The company made adulterated and potentiallyoff its non-core business into a separate company, which will unsafe drugs that were illegal to sell, it claimed.then be listed on the Singapore Stock Exchange. Hospitalsoperator Fortis, controlled by billionare brothers Malvinder andShivinder Singh, expects the restructuring to be completed by Global News Updatethe middle of next month. Valeant gives up on bid to buy IstaThe initial public offering is likely to hit the market in May or Valeant Pharmaceuticals International, pharmaceuticalJune this year. company, headquartered in Canada, has withdrawn its offer to acquire Ista Pharmaceuticals, a US based pharmaceutical3.) Regulations/Legal company that specializes in ophthalmic pharmaceutical products, a fortnight after upping its bid for the eye specialist.Orchid Pharma receives USFDA nod for Levofloxacin TabsANDA Just before Christmas, Valeants $6.50 per share offer, which valued Ista at $314 million, was dismissed as "grosslyThe Chennai-based global pharma major, Orchid Chemicals & inadequate" by the latter. However, Valeant then raised itsPharmaceuticals Ltd has received approval from the US FDA for initial proposal to $7.50 per share in cash and set a target priceits ANDA (Abbreviated New Drug Application) for Levofloxacin of $8.50 per share in cash, subject to one week of due diligence.Tablets in the 250 mg, 500 mg and 750 mg strengths. Amgen hits acquisition trail to snap up Micromet as profits slipLupin gets USFDA approval for diabetes drug Amgen, a international biotechnology company, headquarteredDrug firm Lupin has received approval from the US health in California, has opened its wallet and unveiled plans to buyregulator for its Metformin Hydrochloride Extended Release Micromet, a biotech with its R&D centre in Munich andtablets, used in treating diabetes. The companys US-based headquarters in Rockville, USA, for $1.16 billion.subsidiary Lupin Pharmaceuticals Inc has received tentativeapproval from US Food and Drug Administration (USFDA) for Amgen is offering $11 per share in cash, and the acquisitionMetformin tablets in strengths of 500 mg and 1,000 mg. Lupins includes blinatumomab, a bispecific T cell engager (BiTE)Metformin HCl ER Tablets are the AB-rated generic equivalent of antibody in Phase II for acute lymphoblastic leukaemia. The drugSantarus Incs Glumetza HCl ER Tablets. According to IMS is also in studies for non-Hodgkins lymphoma.Health data, Glumetza HCl ER tablets in strengths of 500 mg and1,000 mg had annual US sales of nearly USD 58 million for the 12 The companies already have a partnership in place. In July lastmonths to September, 2011. year, they signed a deal involving the development of BiTE antibodies against three undisclosed solid tumour targets.Ranbaxy settles row with USFDA; to upgrade plants in Indiaand US Micromets pipeline includes solitomab, a BiTE antibody inRanbaxy Laboratories has agreed to make significant changes in Phase I for advanced solid tumours. Amgen will also be entitledits manufacturing facilities in India and the US as part of a to milestone and royalties from the companys existing licenseessettlement that seeks to end wide-ranging investigations against of BiTE (such as Sanofi, AstraZeneca, Boehringer Ingelheim andthe drug maker by the US regulatory authorities. Bayer) and other technologies.A consent decree, signed between Ranbaxy and the US Food Celgene to acquire Avilaand Drug Administration (FDA) last month and filed in a US court Celgene Corp, a manufacturer of drug therapies for cancer andon Wednesday, extends the ban on supply of drugs from four inflammatory disorders, headquartered in New Jersey, is toplants to the US market until the Indian drug maker resolves the acquire privately-held Avila Therapeutics in a deal that could beproblems at these facilities, dashing hopes of the embargo being worth up to $925 million.lifted immediately after the settlement. Celgene is paying $350 million in cash, plus up to $195 millionThe US Department of Justice (DoJ), which filed the consent for milestones related to the progress of AVL-292, an oraldecree at the request of the FDA, said Ranbaxy had not keptResearch DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projectsfor prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’sTop 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
  • 7. FOUR-S PharmaHealth Trackcovalent drug that inhibits Bruton’s tyrosine kinase which stockholder rights agreement, which is "designed to detercurrently in Phase I for non-Hodgkin’s lymphoma, B cell chronic coercive or otherwise unfair takeover tactics". Earlier this week,lympocytic leukaemia and rheumatoid arthritis. the Swiss major, having been rebuffed by Illuminas board a number of times over the last month, made an unsolicited offerThe deal also includes up to $380 million in potential milestone of $44.50 a share in cash, which represents a premium of aboutpayments contingent upon the development and approval of 18% to Illuminas stock price on January 24.candidates generated from Avilas Avilomics platform. The rights agreement means that Illumina shareholders can buyIllumina adopts poison pill to deter Roche approach $550 in common shares for just $275 if a bidder acquires 15% of the company’s stock. The effect of this would be make IlluminaIllumina is adopting a poison pill in a bid to block Roche’s $5.7 more expensive to acquire.billion hostile takeover offer.The US company, which develops tools and systems for theanalysis of genetic variation and function, has announced a Events Calendar India Pharma Convention BioAsia 2012: The Global Biobusiness Forum Date: Feb 12, 2012 Date: 9 Feb 12 – 11 Feb 2012 Venue: DIPSAR, Delhi Venue: Hyderabad International Convention Centre, Hyderabad Organizer: BioAsia Organizer: Udyog Development Foundation Tel: 91 – 40 – 66446477 website: www.udfoundation.com E-mail: info@bioasia.in Medical Fair India PHARMA Pro&Pack 2013 Date: 2 Mar-4 Mar, 2012 Date: Apr 24-26, 2012 Venue: Bombay exhibition center, Mumbai Venue: Mumbai exhibition center, Goregaon, Mumbai Webmail: http://ems2012.in/ Website: http://www.pharmapropack.com Organizer : Messe Duesseldorf Email: contact@pharmapropack.com http://www.medicalfair-india.com/Research DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projectsfor prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’sTop 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
  • 8. FOUR-S PharmaHealth Track Stock Market Update As on 21 Jan 2012 Market Cap Price Percentage Change (%) In `Mn In ` 1W 1M 3M 6M 1 Year SUN PHARMACE 547616 529 2.89 5.62 8.13 5.23 8.28 DR.REDDYS L 287598 1696 -0.64 4.74 8.05 4.97 -1.63 CIPLA LTD. 266409 332 -0.70 2.09 16.08 5.76 -4.35 LUPIN LTD 197597 442 2.62 3.15 -6.22 -4.63 -5.05 RANBAXY LABO 195380 463 0.84 18.39 -6.65 -12.90 -17.01 GLAXOSMITH 166645 1967 0.13 6.42 -6.40 -14.76 -13.40 CADILA HEALTH 133844 654 -3.64 -8.16 -13.70 -26.20 -21.57 DIVIs LAB 103787 782 -0.22 5.27 7.16 -5.62 24.01 GLENMARK PHA 86251 319 1.55 13.82 9.99 1.54 0.02 APOLLO HOSPITAL 84015 625 -3.55 15.35 17.83 22.32 27.13 PIRAMA HEALTH 71786 416 0.59 12.31 16.50 3.44 -9.66 BIOCON LTD 54980 275 1.76 5.98 -21.81 -26.86 -26.65 OPTO CIRCUIT 41576 223 9.03 27.25 -4.06 -15.20 -9.65 IPCA LAB LTD 35016 279 1.22 10.91 13.60 -16.88 -14.08 JUBILANT ORG 28798 181 -4.05 7.98 -9.40 -18.47 -28.51 AUROBINDO PH 28195 97 -6.71 12.73 -20.27 -41.97 -60.26 ORCHID CHEM 10785 153 7.07 24.21 0.52 -32.13 -48.87 BSE SENSEX 17,605 2.2 10.5 0.7 -1.9 -4.6 NSE NIFTY 15,695 -4.1 -9.0 -2.8 -12.1 -18.8 BSE HEALTHCARE 5,326 2.3 11.8 1.1 -1.5 -3.6 Quarterly Results `in millionCompanies Revenue EBITDA PAT Margins JAS’ OND’ OND’ YoY OND’ OND’ YoY OND’ OND’ YoY EBITDA% NPM % FY10 FY11 FY10 FY11 FY10 FY11 FY’11 FY’11DR.REDDYS L 18985.10 27691.90 45.9 3801.70 8688.20 128.5 2731.40 5129.60 87.8 31.37 18.52RANBAXY LABO 19283.60 20955.31 8.7 2483.89 -769.17 -131.0 3079.36 -4645.80 -250.9 -3.67 -22.17SUN PHARMACE 13314.20 18946.00 42.3 4670.40 7840.40 67.9 5036.50 5977.40 18.7 41.38 31.55LUPIN LTD 15102.10 18189.30 20.4 2972.60 3735.00 25.6 2240.30 2350.60 4.9 20.53 12.92CIPLA LTD. 16343.90 17780.20 8.8 3665.60 4376.10 19.4 2630.10 3089.70 17.5 24.61 17.38CADILA HEALTH 11668.10 13832.20 18.5 2561.70 2615.90 2.1 1620.10 1492.10 -7.9 18.91 10.79JUBILANT ORG 8689.70 10884.90 25.3 1321.50 2083.90 57.7 441.10 -783.90 -277.7 19.14 -7.20AUROBINDO PH 11126.20 10753.00 -3.4 2542.20 -707.90 -127.8 1983.20 -801.60 -140.4 -6.58 -7.45GLENMARK PHA 7491.41 10313.12 37.7 1338.91 1028.65 -23.2 865.25 461.18 -46.7 9.97 4.47APOLLO HOSP 5864.00 6997.50 19.3 996.00 1165.00 17.0 495.50 557.60 12.5 16.65 7.97IPCA LAB LTD 4663.60 6148.30 31.8 909.90 1113.90 22.4 639.50 639.30 0.0 18.12 10.40GLAXOSMITH 5892.70 6146.20 4.3 2159.60 1830.40 -15.2 1578.10 1458.60 -7.6 29.78 23.73OPTO CIRCUIT 4176.60 6112.94 46.4 1228.18 1710.36 39.3 956.75 1250.85 30.7 27.98 20.46PIRAMA HEALTH 4026.90 5587.00 38.7 -325.60 -502.10 54.2 603.30 85.20 -85.9 -8.99 1.52BIOCON LTD 5113.80 5185.10 1.4 1642.40 1287.20 -21.6 1007.60 848.50 -15.8 24.82 16.36ORCHID CHEM 3817.97 4194.92 9.9 734.77 1059.09 44.1 240.15 -565.68 -335.6 25.25 -13.48Divis Lab 3,150 4174.20 32.5 1,235 1,511.00 22.4 1,015.70 1225.50 20.7 36.20 29.36 OND:Oct-Nov-Dec quarterResearch DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projectsfor prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
  • 9. FOUR-S PharmaHealth Track TTM Results `in million Revenue EBITDA PAT Margins TTM TTM TTM TTM TTM TTM TTM EBITDACompanies Dec 10 Dec 11 YoY Dec 10 Dec 11 YoY Dec 10 Dec 11 YoY % NPM %DR.REDDYS L 81619 90326 10.7 16824 21710 29.0 11769 14141 20.2 24.0 15.7RANBAXY LABO 81411 82864 1.8 10305 7052 -31.6 8316 19 -99.8 8.5 0.0SUN PHARMACE 60315 65947 9.3 18986 22156 16.7 19399 21403 10.3 33.6 32.5LUPIN LTD 62657 65881 5.1 13064 13827 5.8 9424 9551 1.3 21.0 14.5CIPLA LTD. 62468 63987 2.4 13564 14274 5.2 9630 10090 4.8 22.3 15.8CADILA HEALTH 45831 46964 2.5 10466 10388 -0.7 7416 6735 -9.2 22.1 14.3AUROBINDO PH 45361 44988 -0.8 9937 6687 -32.7 3887 1105 -71.6 14.9 2.5JUBILANT ORG 37492 39699 5.9 6888 7650 11.1 2714 1651 -39.2 19.3 4.2GLENMARK PHA 34645 37469 8.2 6580 6270 -4.7 4336 3932 -9.3 16.7 10.5APOLLO HOSPITAL 24497 25630 4.6 3946 4115 4.3 1937 1999 3.2 16.1 7.8GLAXOSMITH 22371 22626 1.1 7905 7576 -4.2 4215 4096 -2.8 33.5 18.1IPCA LAB LTD 20815 22199 6.7 4183 4387 4.9 2622 2621 0.0 19.8 11.8BIOCON LTD 21614 21689 0.3 5700 5345 -6.2 3564 3427 -3.8 24.6 15.8OPTO CIRCUIT 18144 20451 12.7 4907 5397 10.0 4016 4457 11.0 26.4 21.8PIRAMA HEALTH 18517 20055 8.3 -34 -211 517.6 4055 3549 -12.5 -1.1 17.7ORCHID CHEM 16649 17088 2.6 4123 4447 7.9 1534 1528 -0.4 26.0 8.9Divis Lab 15022 16069 7.0 5901 6177 4.7 4850 5059 4.3 38.4 31.5 OND quarter results not declared for Aurobindo, Apollo, Cipla, Glaxosmith, Orchid, Standalone results for Cipla, Apollo, Orchid, Glaxosmith, Divis Lab and Ipca Lab Ranbaxy and Sun Pharma BSE Healthcare Index movement in last 2 weeks Research Desk Four-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projects for prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
  • 10. FOUR-S PharmaHealth TrackFour-S Services Pvt Ltd Founded in 2002, Four-S has a strong & successful track record of genuine, accurate and objective advice to top Indian & global companies & PE Firms. Four-S has already proven success in corporate finance, strategy consulting, fund-raising, investment banking and investor relations mandates with 100+ corporates and large PE fundsFour-S, trusted advisor to top Indian & Global Cos Offering comprehensive bouquet of services to Private Equity FundsResearch DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projectsfor prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
  • 11. FOUR-S PharmaHealth Track About Four-S Services Four-S Services provides customized business and financial research to organizations across the globe. The company also provides Investor Relations consulting to corporate based on in-depth sectoral and company research. The company has an impressive client profile and a team of senior analysts covering key sectors including Finance & Banking, IT & Telecom, Retail, Media & Entertainment, Pharmaceuticals, Infrastructure and Manufacturing amongst others. For further information on the company please visit www.four-s.com Disclaimer The information contained herein has been obtained from sources believed to be reliable but is not necessarily complete and its accuracy cannot be guaranteed. No representation, warranty, guarantee or undertaking, express or implied, is made as to the fairness, accuracy or completeness of any information, projections or opinion contained in this document or upon which any such projections or opinions have been based. Four-S Services Pvt Ltd. will not accept any liability, whatsoever with respect to the use of this document or its content. This document has been distributed for information purposes only and does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities. This document shall not form the basis of and should not be relied upon in connection with any contract or commitment whatsoever. This document is not to be reported or copied or made available to others. The Company may from time to time solicit from, or perform consulting, or other services for, any company mentioned in this document.Research DeskFour-S Services is Indias leading provider of high-end research, financial consulting and Investment banking services. We have executed projectsfor prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s